Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial
The DOI matches its Crossref record.
Abstract
We report a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNB) in 372 ambulatory patients with relapsing-remitting multiple sclerosis (MS). Entry criteria included an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 and at least two exacerbations in the previous 2 years. One-third of the patients received placebo, one-third 1.6 million international units (MIU) of IFNB, and one-third 8 MIU of IFNB, self-administered by subcutaneous injections every other day. The primary end points were differences in exacerbation rates and proportion of patients remaining exacerbation-free. The annual exacerbation rate for patients receiving placebo was 1.27; for 1.6 MIU IFNB, 1.17; and for 8 MIU IFNB, 0.84 after 2 years. Exacerbation rates were significantly lower in both treatment groups compared with the placebo group (8 MIU versus placebo, p = 0.0001; 1.6 MIU versus placebo, p = 0.0101; and 8 MIU versus 1.6 MIU, p = 0.0086), suggesting a dosage effect. The reduction in exacerbation severity in the 8 MIU group was attributable to a twofold reduction in the frequency of moderate and severe attacks. More patients in the 8 MIU group (n = 36) were exacerbation-free at 2 years compared with the placebo group (n = 18; p = 0.007). EDSS scores changed little from baseline in both the placebo and treatment arms. Accordingly, a significant change in disability could not be discerned in this trial. Finally, in serial MRIs, MS activity was significantly less in the high-dose IFNB group.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Items 101–125 of 125
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy
Sorensen, P. S., Koch-Henriksen, N., Ross, C., Clemmesen, K. M., Bendtzen, K., & the Danish Multiple Sclerosis Study Group (2005) · Neurology · doi:10.1212/01.wnl.0000166049.51502.6a · Cited by 193
Self-citationPredictors of long‐term disability accrual in relapse‐onset multiple sclerosis
Jokubaitis, V. G., Spelman, T., Kalincik, T., Lorscheider, J., Havrdova, E., Horakova, D., Duquette, P., Girard, M., Prat, A., Izquierdo, G., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24682 · Cited by 191
Cadavid, D., Wolansky, L. J., Skurnick, J., Lincoln, J., Cheriyan, J., Szczepanowski, K., Kamin, S. S., Pachner, A. R., Halper, J., & Cook, S. D. (2009) · Neurology · doi:10.1212/01.wnl.0000345970.73354.17 · Cited by 185
Mathur, V., Burai, R., Vest, R. T., Bonanno, L. N., Lehallier, B., Zardeneta, M. E., Mistry, K. N., Do, D., Marsh, S. E., Abud, E. M., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.032 · Cited by 175
Interferon β for Multiple Sclerosis
Jakimovski, D., Kolb, C., Ramanathan, M., Zivadinov, R., & Weinstock-Guttman, B. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a032003 · Cited by 170
Key issues in the diagnosis and treatment of multiple sclerosis: An overview
O’Connor, P. (2002) · Neurology · doi:10.1212/wnl.59.6_suppl_3.s1 · Cited by 170
Cytokines and the immune response
Van der Meide, P. H., & Schellekens, H. (1996) · Biotherapy · doi:10.1007/bf01877210 · Cited by 166
Sen, T., Saha, P., Gupta, R., Foley, L. M., Jiang, T., Abakumova, O. S., Hitchens, T. K., & Sen, N. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0718-19.2019 · Cited by 164
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
Kalincik, T., Horakova, D., Spelman, T., Jokubaitis, V., Trojano, M., Lugaresi, A., Izquierdo, G., Rozsa, C., Grammond, P., Alroughani, R., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24339 · Cited by 162
Managing the symptoms of multiple sclerosis: A multimodal approach
Crayton, H. J., & Rossman, H. S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.04.005 · Cited by 159
Epidemiology and natural history of multiple sclerosis: new insights
Kantarci, O., & Wingerchuk, D. (2006) · Current Opinion in Neurology · doi:10.1097/01.wco.0000227033.47458.82 · Cited by 156
Mohr, D. C., Goodkin, D. E., Likosk, W., Gatto, N., Neilley, L. K., Griffin, C., & Stiebling, B. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600200502 · Cited by 131
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Stüve, O., & Bennett, J. L. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00003.x · Cited by 123
Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., & Cazzato, G. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00225-9 · Cited by 81
Interferon γ- and interleukin-4-secreting cells in multiple sclerosis
Lu, C.-Z., Jensen, M. A., & Arnason, B. G. W. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90241-p · Cited by 77
Update on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55
Costello, F., Stüve, O., Weber, M. S., Zamvil, S. S., & Frohman, E. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328122de1b · Cited by 46
Palace, J., Duddy, M., Lawton, M., Bregenzer, T., Zhu, F., Boggild, M., Piske, B., Robertson, N. P., Oger, J., Tremlett, H., et al. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318360 · Cited by 44
Interferon-β1bin multiple sclerosis
Buttmann, M., & Rieckmann, P. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.3.227 · Cited by 43
Tilling, K., Lawton, M., Robertson, N., Tremlett, H., Zhu, F., Harding, K., Oger, J., & Ben-Shlomo, Y. (2016) · Health Technology Assessment · doi:10.3310/hta20810 · Cited by 43
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Milo, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613504021 · Cited by 38
Plasma chitotriosidase activity in multiple sclerosis
Comabella, M., Domínguez, C., Rio, J., Martín-Gallán, P., Vilches, A., Vilarrasa, N., Espejo, C., & Montalban, X. (2009) · Clinical Immunology · doi:10.1016/j.clim.2008.12.004 · Cited by 34
Consensus guidelines for the diagnosis and treatment of multiple sclerosis
Yamout, B., Alroughani, R., Al-Jumah, M., Khoury, S., Abouzeid, N., Dahdaleh, M., Alsharoqi, I., Inshasi, J., Hashem, S., Zakaria, M., et al. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.787979 · Cited by 25
Insights and challenges on animal models for progressive multiple sclerosis
Nalepa, I. F., Haahr, N. O., Bekiaris, V., Jakobsen, M. R., Asuni, A. A., & Benmamar-Badel, A. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03805-3 · Cited by 1
Metadata
- Authors
- The IFNB Multiple Sclerosis Study Group
- Venue
- Neurology
- Published
- 1993-04
- Volume
- 43
- Issue
- 4
- Pages
- 655-655
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W4210548604
- Cited by
- 2,085
- References
- 0
- FWCI
- 51.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.